Kera Capital Partners Inc. Buys New Holdings in Zoetis Inc. $ZTS

Key Points

• Kera Capital Partners Inc. has acquired a new position in Zoetis Inc., purchasing 2,526 shares valued at approximately $394,000 during the 2nd quarter.
• Analysts have mixed views on Zoetis, with five firms maintaining a Buy rating and others downgrading their ratings and price targets, resulting in a consensus rating of "Moderate Buy" with a target price of $200.88.
• Zoetis reported earnings of $1.76 EPS in its last quarterly results, exceeding expectations and marking a 4.2% increase in revenue year-over-year.

Kera Capital Partners Inc. bought a new position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 2,526 shares of the company's stock, valued at approximately $394,000.

Several other large investors have also made changes to their positions in the business. Lindbrook Capital LLC raised its stake in shares of Zoetis by 1.8% during the 1st quarter. Lindbrook Capital LLC now owns 3,715 shares of the company's stock worth $612,000 after buying an additional 65 shares during the period. Quotient Wealth Partners LLC raised its stake in shares of Zoetis by 2.3% during the 1st quarter. Quotient Wealth Partners LLC now owns 3,167 shares of the company's stock worth $521,000 after buying an additional 72 shares during the period. Broadway Wealth Solutions Inc. raised its stake in shares of Zoetis by 4.4% during the 1st quarter. Broadway Wealth Solutions Inc. now owns 1,746 shares of the company's stock worth $287,000 after buying an additional 73 shares during the period. Menard Financial Group LLC raised its stake in shares of Zoetis by 3.8% during the 1st quarter. Menard Financial Group LLC now owns 2,032 shares of the company's stock worth $305,000 after buying an additional 75 shares during the period. Finally, Anchor Investment Management LLC raised its stake in shares of Zoetis by 4.9% during the 1st quarter. Anchor Investment Management LLC now owns 1,618 shares of the company's stock worth $266,000 after buying an additional 75 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently commented on ZTS. Argus reissued a "buy" rating and issued a $190.00 price objective on shares of Zoetis in a research note on Tuesday, September 9th. Leerink Partnrs downgraded Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Leerink Partners downgraded Zoetis from an "outperform" rating to a "market perform" rating and reduced their price objective for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Piper Sandler increased their price objective on Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a research note on Monday, August 11th. Finally, Stifel Nicolaus downgraded Zoetis from a "buy" rating to a "hold" rating and reduced their price objective for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Five equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, Zoetis currently has a consensus rating of "Moderate Buy" and a consensus target price of $200.88.

Zoetis Stock Performance

NYSE ZTS opened at $148.33 on Friday. The stock has a market cap of $65.74 billion, a PE ratio of 25.53, a P/E/G ratio of 2.42 and a beta of 0.89. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33. The stock has a fifty day simple moving average of $152.32 and a 200-day simple moving average of $157.26.

Zoetis (NYSE:ZTS - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company had revenue of $2.46 billion during the quarter, compared to analysts' expectations of $2.41 billion. During the same period last year, the business posted $1.56 EPS. Zoetis's revenue for the quarter was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.